RADAR: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtRasentan - A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Efficacy.

Trial Profile

RADAR: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtRasentan - A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Efficacy.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Atrasentan (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms RADAR
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 26 Jul 2017 Results (n=257) of this and 2 other phase II studies, published in the Clinical Therapeutics.
    • 20 May 2013 Results presented during a late breaking clinical trials scientific session at the 2013 European Renal Association-European Dialysis and Transplant Association, according to an AbbVie media release.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top